Olga P Ajsuvakova1, Alexey A Tinkov2, Desiree Willkommen3, Anastasia A Skalnaya4, Alexey B Danilov5, Anna A Pilipovich5, Michael Aschner6, Anatoly V Skalny7, Bernhard Michalke8, Margarita G Skalnaya9. 1. I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya St., 8-2, 119991 Moscow, Russia; Peoples' Friendship University of Russia (RUDN University), Miklukho-Maklay St., 10/2, Moscow 117198, Russia; Federal Scientific Center of Biological Systems and Agrotechnologies of the Russian Academy of Sciences, 9 Yanvarya St., 29, 460000 Orenburg, Russia. Electronic address: oajsuvakova@gmail.com. 2. I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya St., 8-2, 119991 Moscow, Russia; P.G. Demidov Yaroslavl State University, Sovetskaya st., 14, 150003 Yaroslavl, Russia; Federal Scientific Center of Biological Systems and Agrotechnologies of the Russian Academy of Sciences, 9 Yanvarya St., 29, 460000 Orenburg, Russia. 3. RECIPE Chemicals and Instruments GmbH, Sternstraße 5A, 85386 Eching, Munich, Germany. 4. M.V. Lomonosov Moscow State University, Leninskie Gory, 1, 119991 Moscow, Russia. 5. I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya St., 8-2, 119991 Moscow, Russia. 6. Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA. 7. I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya St., 8-2, 119991 Moscow, Russia; Peoples' Friendship University of Russia (RUDN University), Miklukho-Maklay St., 10/2, Moscow 117198, Russia; Federal Scientific Center of Biological Systems and Agrotechnologies of the Russian Academy of Sciences, 9 Yanvarya St., 29, 460000 Orenburg, Russia. 8. Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. 9. I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya St., 8-2, 119991 Moscow, Russia; Peoples' Friendship University of Russia (RUDN University), Miklukho-Maklay St., 10/2, Moscow 117198, Russia.
Abstract
BACKGROUND: The objective of this pilot study was to assess iron (Fe), copper (Cu), zinc (Zn), and manganese (Mn) status (hair, serum, and urine) and speciation (serum) in Parkinson's disease (PD) patients. METHODS: A pilot study involving a total of 27 subjects (13 PD patients, 14 controls) was performed. Serum, urine, and hair metal content was assessed using ICP-MS. Speciation analysis of Cu, Zn, Fe, and Mn was performed using a hybrid HPLC-ICP-MS system. RESULTS: Group comparisons did not reveal any significant group difference in serum Cu, Zn, Fe, and Mn total metal level between PD patients and controls. Speciation analysis revealed a significant decrease in Cu/ceruloplasmin copper in association with elevation of low-molecular weight species (amino acids)-bound copper. It is proposed that in PD, binding of Cu(II) ions to ceruloplasmin is reduced and free copper ions coordinate with low molecular weight ligands. The level of Mn-albumin complexes in PD patients was more than 4-fold higher as compared to the respective value in the control group. The observed difference may be considered as a marker of redistribution between high and low molecular weight ligands. CONCLUSIONS: Metal speciation is significantly affected in serum of PD-patients. These findings are indicative of the potential role of metal metabolism and PD pathogenesis, although the exact mechanisms of such associations require further detailed studies.
BACKGROUND: The objective of this pilot study was to assess iron (Fe), copper (Cu), zinc (Zn), and manganese (Mn) status (hair, serum, and urine) and speciation (serum) in Parkinson's disease (PD) patients. METHODS: A pilot study involving a total of 27 subjects (13 PDpatients, 14 controls) was performed. Serum, urine, and hair metal content was assessed using ICP-MS. Speciation analysis of Cu, Zn, Fe, and Mn was performed using a hybrid HPLC-ICP-MS system. RESULTS: Group comparisons did not reveal any significant group difference in serum Cu, Zn, Fe, and Mn total metal level between PDpatients and controls. Speciation analysis revealed a significant decrease in Cu/ceruloplasmincopper in association with elevation of low-molecular weight species (amino acids)-bound copper. It is proposed that in PD, binding of Cu(II) ions to ceruloplasmin is reduced and free copper ions coordinate with low molecular weight ligands. The level of Mn-albumin complexes in PDpatients was more than 4-fold higher as compared to the respective value in the control group. The observed difference may be considered as a marker of redistribution between high and low molecular weight ligands. CONCLUSIONS: Metal speciation is significantly affected in serum of PD-patients. These findings are indicative of the potential role of metal metabolism and PD pathogenesis, although the exact mechanisms of such associations require further detailed studies.
Authors: Olga P Ajsuvakova; Margarita G Skalnaya; Bernhard Michalke; Alexey A Tinkov; Eugeny P Serebryansky; Mikhail Yu Karganov; Yulia S Medvedeva; Anatoly V Skalny Journal: Biometals Date: 2021-05-18 Impact factor: 2.949